Hepatocellular Carcinoma
Clinical research is centered on intermediate-stage hepatocellular carcinoma, with attention to disease burden that extends beyond the up-to-7 criteria. The funded trial activity focuses on treatment strategies for liver cancer in patients who are not suited to straightforward local management alone.
- Intermediate-stage HCC
- Beyond up-to-7 criteria
- Liver malignancy
The trial landscape reflects interest in refining care for patients with hepatocellular carcinoma where tumor extent and clinical complexity require specialized oncologic decision-making.
Locoregional Therapy
One major therapeutic area is transarterial chemoembolization and transarterial radioembolization, both central to the management of intermediate-stage disease. These approaches are represented as key comparators in the funded research environment.
- TACE
- TARE
- Locoregional treatment
Interest in these modalities highlights a focus on regional tumor control and interventional oncology options for liver-directed therapy.
Systemic and Combination Oncology
The sponsor’s research includes regorafenib and pembrolizumab, reflecting activity in combined targeted therapy and immunotherapy strategies for liver cancer. This area connects systemic treatment with disease-specific management in hepatobiliary oncology.
- Regorafenib
- Pembrolizumab
- Targeted therapy
- Immuno-oncology
The therapeutic interest lies in integrating systemic agents with established locoregional approaches for patients with intermediate-stage HCC.
Oncology Outcomes Assessment
Research activity is oriented toward clinical endpoints used in solid tumor oncology, including progression-free survival and response assessment with mRECIST for hepatocellular carcinoma. These measures support evaluation of treatment benefit in liver cancer populations.
- Progression-free survival
- mRECIST
- Tumor response assessment
This area emphasizes clinically relevant endpoints for oncology treatment comparison in HCC.
